4-chloro-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid ethyl ester | 111205-30-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-chloro-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid ethyl ester
• 英文别名: ethyl 4-chloro-5,6,7,8-tetrahydroquinoline-3-carboxylate
• CAS: 111205-30-2
• 化学式: C₁₂H₁₄ClNO₂
• 分子量: 239.702
• InChiKey: DKDMXYWZQVIKCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  39.2
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (4-甲氧基苯基)肼 、 4-chloro-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid ethyl ester 在 sodium hydroxide 作用下， 以 甲苯 为溶剂， 生成 2-(4-methoxyphenyl)-2,3,6,7,8,9-hexahydropyrazolo[4,3-c]quinolin-3(5H)-one
  参考文献：
  名称：

  Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine

  摘要：

  公式IA或IB的化合物其中A代表可选择取代的饱和双价基团，与其连接的两个碳原子一起表示从可选择取代的融合环中选择的5、6或7元碳环或杂环，包括可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吩、二氢吡咯、四氢吡啶和四氢氮杂二氢吡喃; R1代表低碳基、苯基，或由低碳基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表芳香杂环基团，例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基; R2、R3、R3'为氢或低碳基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓受体调节剂。还公开了作为苯二氮卓受体调节剂有用的药物组合物、制备方法和某些中间体。

  公开号：

  US04602014A1
• 作为产物：
  描述：

  4-hydroxy-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid ethyl ester 在 三氯氧磷 作用下， 反应 1.0h， 生成 4-chloro-5,6,7,8-tetrahydro-quinoline-3-carboxylic acid ethyl ester
  参考文献：
  名称：

  [EN] TRICYCLIC HETEROCYCLIC COMPOUNDS AS GABA A MODULATORS
  [FR] COMPOSÉS ORGANIQUES

  摘要：

  公开号：

  WO2009021957A3

文献信息

• Treating anxiety with certain ring-fused pyrazolo[3,4-d]-pyridin-3-one
  申请人：Ciba-Geigy Corporation

  公开号：US04740512A1

  公开（公告）日：1988-04-26

  Compounds of the formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式IA或IB的化合物，其中A代表一个可选择替代的饱和二价基团，与其连接的两个碳原子一起代表一个选择自可选择替代的融合环的5、6或7成员碳环或杂环，包括可选择替代的融合环己烯、环己烯、环庚烯、二氢噻吩、二氢硫吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吡喃、二氢吡咯、四氢吡啶和四氢氮杂环; R.sub.1代表低碳烷基、苯基，或者被低碳烷基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或者R.sub.1代表芳香杂环基，例如可选择替代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基; R.sub.2、R.sub.3、R.sub.3'为氢或低碳烷基; 和药用盐; 用作治疗神经系统疾病的苯二氮卓类受体调节剂。还公开了作为苯二氮卓类受体调节剂有用的药物组合物、制备方法和某些中间体。
• Ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives as benzodiazepine
  申请人：Ciba-Geigy Corporation

  公开号：US04602014A1

  公开（公告）日：1986-07-22

  Compounds of the formula formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  公式IA或IB的化合物其中A代表可选择取代的饱和双价基团，与其连接的两个碳原子一起表示从可选择取代的融合环中选择的5、6或7元碳环或杂环，包括可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吡喃、四氢噻吩、二氢呋喃、二氢吡喃、四氢氧吩、二氢吡咯、四氢吡啶和四氢氮杂二氢吡喃; R1代表低碳基、苯基，或由低碳基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表芳香杂环基团，例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基; R2、R3、R3'为氢或低碳基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓受体调节剂。还公开了作为苯二氮卓受体调节剂有用的药物组合物、制备方法和某些中间体。
• Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives in treating
  申请人：Ciba-Geigy Corporation

  公开号：US04647566A1

  公开（公告）日：1987-03-03

  Compounds of the formula formula IA or IB ##STR1## wherein A represents an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.3 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  化合物的结构式为IA或IB，其中A代表可选择地取代的饱和双价基团，与其连接的两个碳原子一起代表从可选择取代的融合环戊烯、环己烯、环庚烯、二氢噻吩、二氢噻吩吡喃、四氢噻环戊、二氢呋喃、二氢吡喃、四氢氧杂环戊、二氢吡咯、四氢吡啶和四氢氮杂环庚中选择的融合5、6或7-成员碳环或杂环环; R1代表低碳烷基、苯基，或由低碳烷基、低碳氧基、卤素或三氟甲基单取代或双取代的苯基; 或R1代表选择自例如可选择取代的吡啶基、喹啉基、异喹啉基、嘧啶基和噻唑基的芳香杂环基; R2、R3、R3'为氢或低碳烷基; 和药学上可接受的盐; 用作治疗神经系统疾病的苯二氮卓类受体调节剂。还公开了作为苯二氮卓类受体调节剂有用的药物组合物、制备方法和某些中间体。
• Certain ring-fused pyrazolo[3,4-d]-pyridin-3-one derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US04814450A1

  公开（公告）日：1989-03-21

  Compounds of the formula formula IA or IB ##STR1## wherein A represent an optionally substituted saturated divalent grouping which together with the two carbon atoms to which it is attached represents a fused 5-, 6- or 7-membered carbocyclic or heterocyclic ring selected from optionally substituted fused cyclopenteno, cyclohexeno, cyclohepteno, dihydrothieno, dihydrothiopyrano, tetrahydrothiepino, dihydrofuro, dihydropyrano, tetrahydrooxepino, dihydropyrrolo, tetrahydropyrido and tetrahydroazepino; R.sub.1 represents lower alkyl, phenyl, or phenyl mono- or disubstituted by lower alkyl, lower alkoxy, halogen or trifluoromethyl; or R.sub.1 represents an aromatic heterocyclic radical selected from e.g. optionally substituted pyridyl, quinolyl, isoquinolyl, pyrimidyl and thiazolyl; R.sub.2, R.sub.3, R.sub.4 ' are hydrogen or lower alkyl; and pharmaceutically acceptable salts; are useful as benzodiazepine receptor modulators for the treatment of nervous system disorders. Pharmaceutical compositions, methods of preparation and certain intermediates useful as benzodiazepine receptor modulators are also disclosed.

  式IA或IB的化合物##STR1##其中A代表一个可以选择性取代的饱和二价基团，与其相连的两个碳原子共同代表一种选择自可选择性取代的融合的5-,6-或7-成员碳环或杂环，所述环选自可选择性取代的融合的环戊烯基，环己烯基，环庚烯基，二氢噻吩基，二氢噻吩并吡喃基，四氢噻环并吡喃基，二氢呋喃基，二氢吡喃基，四氢氧环并吡喃基，二氢吡咯基，四氢吡啶基和四氢氮杂环并吡喃基；R.sub.1代表较低的烷基，苯基，或被较低的烷基，较低的烷氧基，卤素或三氟甲基单取代或双取代的苯基；或R.sub.1代表选自例如可选择性取代的吡啶基，喹啉基，异喹啉基，嘧啶基和噻唑基的芳香族杂环基；R.sub.2，R.sub.3，R.sub.4'为氢或较低的烷基；以及药学上可接受的盐；用作苯二氮平受体调节剂，用于治疗神经系统疾病。还公开了制药组合物，制备方法和某些中间体，这些中间体用作苯二氮平受体调节剂。
• Organic Compounds
  申请人：Hintermann Samuel

  公开号：US20110195950A1

  公开（公告）日：2011-08-11

  The invention relates to compound of the formula I in which R 1 represents an optionally substituted aryl group or an optionally substituted heteroaryl group; R 2 represents hydrogen or a substituent different from hydrogen; R 3 represents an optionally substituted aryl group, cycloalkyl group, heteroaryl group, heterocyclyl group; X 1 represents O, S, NR 4 , CR 4 2 ; X 2 represents O, S, NR 4 , CR 4 2 ; X 3 represents O, S, NR 4 , CR 4 2 ; X 4 represents O, S, NR 4 , CR 4 2 ; R 4 represents hydrogen or a substituent different from hydrogen; R 5 represents hydrogen or alkyl; Y represents O or S; m represents 0, 1, 2 or 3; n represents 0, 1, 2 or 3 in free base form or in acid addition salt form; to its preparation, to its use as medicament and to medicaments comprising it.

  本发明涉及一种式子I的化合物，其中R1代表可选取代的芳基或可选取代的杂芳基；R2代表氢或与氢不同的取代基；R3代表可选取代的芳基、环烷基、杂芳基、杂环烷基；X1、X2、X3和X4分别代表O、S、NR4、CR42；R4代表氢或与氢不同的取代基；R5代表氢或烷基；Y代表O或S；m在自由碱形式或酸盐形式下代表0、1、2或3；n在自由碱形式或酸盐形式下代表0、1、2或3；本发明还涉及其制备方法、作为药物的用途以及包含该化合物的药物。